KLS-13023

KLS-13023 is a synthetic cannabidiol (CBD)-based drug candidate formulated in a gel capsule, developed by Neuropathix (formerly Kannalife) for potential use in humans[1][7][8]. It is designed as a pharmaceutical-grade CBD analog with improved properties over natural CBD, including increased potency and bioavailability. The primary indications under investigation are hepatic encephalopathy and other neurodegenerative or neuropathic conditions such as traumatic brain injury and chemotherapy-induced peripheral neuropathy[1][4][5][7]. The drug remains at the preclinical stage of development. Its mechanism of action is presumed to be similar to that of cannabidiol, potentially involving neuroprotective effects against oxidative stress toxicity relevant to hepatic encephalopathy and modulation of pathways involved in neuropathic pain[3][5].